Compare Adaptive Biotechnologies Corp (ADPT) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Texas Instruments Incorporated — how do they compare? Adaptive Biotechnologies Corp trades at $20.07 (market cap $3.33B), while Texas Instruments Incorporated trades at $304.87 (market cap $266.93B). The key difference: Texas Instruments Incorporated is far larger — about 80.2× Adaptive Biotechnologies Corp's market cap, and Texas Instruments Incorporated pays a 1.94% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TXN | |
|---|---|---|
Market Cap | $3.33B | $266.93B |
Sector | Health | Technology |
52-Week High | $22.37 | $332.35 |
52-Week Low | $10.24 | $153.33 |
Enterprise Value | $3.19B | $275.88B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Texas Instruments (TXN) trades at $303.50, up 3.56% over 24 hours, with a bullish technical signal and strong profitability metrics including a 29.11% net income margin. Recent Q1 2026 earnings beat expectations, and the company announced a CFO transition with Julie Knecht set to succeed Rafael Lizardi in August 2026. Cash flow trends show improving operational performance, with 2025 operating cash flow at $7.15 billion.
The outlook remains positive with analyst consensus pointing to a $310.95 price target and 47.69% buy ratings. Key risks include elevated valuation ratios like a P/E of 51.88 and rising debt-to-asset ratio, now at 40.61% for 2025. Growth is supported by AI-driven demand in data centers, but investors should monitor execution on sequential revenue guidance and competitive pressures in the semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
